Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Total Enrollment

1064 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-03-31

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment (statin or combination) reaching the LDL-C goals according to the updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Survey of Lipid Goal Attainment and Mortality in Patients With High Cardiovascular Risk in Thailand

NCT00684151

Dyslipidemia

COMPLETED

Atorvastatin Study For The Treatment Of High Cholesterol In Patients From Thailand

NCT00647543

Dyslipidemias

COMPLETED PHASE4

The Multicenter Atorvastatin Plaque Stabilization (MAPS) Study

NCT01053065

Symptomatic Carotid Stenosis Hypercholesterolemia Indication for Carotid Endarterectomy

COMPLETED NA

Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

NCT00536965

Hyperlipidemias Atherosclerosis Coronary Heart Disease +3 more

COMPLETED

Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States

NCT01031277

Hypercholesterolemia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

MC MD

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of subject informed consent, Female or male aged = 18 years
* Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention Receiving lipid-lowering drug treatment for at least 15 days.

Exclusion Criteria

* Involvement in the planning and conduct of the study (applies to either AstraZeneca staff or staff at the study site).
* Previous enrolment or randomisation of treatment in the present study
* Participation in a clinical study during the last 90 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No